

1 **Title:** Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal
2 pessaries among women in Kenya.

3

4 **Short title:** Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries
5 among women in Kenya.

6

7 **Authors:** Chemtai Mungo, MD, MPH^{1,2}; Katherine Sorgi¹, Cirillus Ogollah, BSc, DipCM⁴,
8 Brenda Misiko⁴, Cynthia Cheserem⁴, George Githongo⁴, Jackton Omoto, MBChB, MMed³

9

10 **Affiliations**

11 1. Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill, 321
12 S Columbia St, Chapel Hill, North Carolina, 27599, USA.

13 2. Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, 450
14 West Dr, Chapel Hill, North Carolina, 27599, USA

15 3. Department of Obstetrics and Gynecology, Maseno University School of Medicine, P.O,
16 Kisumu, Kenya

17 4. Kenya Medical Research Institute, Busia Rd, Kisumu, Kenya

18

19

20 **Corresponding Author:**

21 Chemtai Mungo, MD, MPH, chemtai_mungo@med.unc.edu

22

23 **Abstract (300-word max):**

24 Cervical cancer remains a significant global health issue, especially in low- and middle-income
25 countries (LMICs), where access to prevention and treatment is limited and women are at a
26 higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has
27 shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including
28 high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the
29 pharmacokinetics of artesunate following intravaginal use, and its implications on malaria
30 resistance, are lacking.

31
32 **Objectives:** The primary objective of this study is to investigate the pharmacokinetics of
33 Artesunate (AS) and its active metabolite, dihydroartemisinin (DHA) following intravaginal use
34 at the dosing and frequency intended for cervical precancer treatment. A secondary objective is
35 to assess safety among study participants.

36
37 **Methods:** We are conducting a single-arm, phase I trial with a sample size of 12 female
38 volunteers. Participants will self-administer artesunate vaginal pessaries in the study clinic daily
39 for 5 consecutive days. Participants will have their blood drawn prior to receiving the first dose
40 of artesunate on day one of the study and then will receive 8 blood draws on study day five, prior
41 to artesunate administration and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and
42 8 hours after pessary administration. Pharmacokinetic parameters of artesunate and DHA will be
43 calculated by way of quantitative analysis of with determination of maximum concentration
44 (C_{max}), time to C_{max} (T_{max}), area under the plasma concentration versus time curve (AUC),
45 apparent clearance, and elimination half-life ($t_{1/2}$).

46

47 Keywords: pharmacokinetics, artesunate, dihydroartemisinin, intravaginal use, cervical
48 precancer, malaria resistance

49

50 **Introduction:**

51 Cervical cancer is the second most common cancer in women globally, with a high
52 prevalence in low- and middle-income countries like Kenya. It is caused by human
53 papillomavirus (HPV) infection but can be prevented through vaccinations or early screening to
54 find precancerous changes in the cervix – also known as cervical intraepithelial neoplasia. While
55 these methods can prevent cervical cancer from developing in women, there are access and
56 resource barriers, especially in LMICs. For instance, HPV vaccinations are new in Kenya and
57 other LMICs, and very few women under the age of 20 have been vaccinated. There are also cost
58 barriers and shortages in healthcare providers. In countries like Kenya and other LMICs where
59 there are few nurses and doctors, many women with cervical precancer are often referred to far
60 away facilities to access treatment and due to costs and other challenges, many are unable to
61 access the referral centers with providers who can offer treatment.

62 These barriers have led to researchers exploring the option of self-administered
63 treatments for cervical precancer to overcome healthcare provider and healthcare resource
64 shortages. One treatment being studied is an intravaginal pessary formulation of the drug
65 Artesunate, which is often used to treat malaria. While a U.S. study has shown its safety and
66 early efficacy for cervical precancer treatment,¹ it is unknown whether intravaginal use of
67 artesunate vaginal inserts at the dosing and frequency used, may result in systemic exposure and
68 hence have implications for malaria resistance. To fill this gap in the literature, this study seeks

69 to investigate the pharmacokinetics of intravaginal artesunate at the dose and frequency used in
70 ongoing cervical precancer treatment studies.

71

72 **Intravaginal Artesunate for Cervical Precancer Treatment**

73 Artesunate (AS), a World Health Organization (WHO) approved malaria drug, is being
74 explored as a potential topical therapy for cervical precancer as its safety and tolerability has
75 long been well established.²⁻⁵ Growing evidence suggests its cytotoxic effects against numerous
76 cancer cell lines both *in vitro* and *in vivo* and have revealed its proposed mechanisms of action
77 include suppressing cell proliferation by inducing G1 and G2M phase cell cycle arrest and
78 modulation of inflammatory pathways characteristic of uncontrolled proliferation and
79 carcinogenesis.⁶⁻⁹ Ferroptosis, an iron-dependent cell death type, is thought to be a key
80 anticancer mechanism for HPV-infected cells.¹⁰ Cancer cells are highly proliferative, requiring a
81 heavy iron load which acts as a cofactor in synthesizing deoxyriboses before cell division.¹¹
82 Development of both high-grade cervical intraepithelial neoplasia (CIN2/3), the precursor lesion
83 of cervical cancer, and cervical cancer are associated with the expression of two viral proteins in
84 the HPV lifecycle, E6 and E7.¹² Epithelial cells that express either or both of these oncoproteins
85 also overexpress the transferrin receptor, and have been shown to have increased levels of
86 intracellular iron compared with normal cells.¹⁰ This observation has been exploited to
87 investigate whether preinvasive cervical cancer (CIN2/3), can be treated with Artesunate, which
88 contains an endoperoxide bridge that reacts with intracellular ferrous iron to generate free
89 radicals, capable of inducing direct oxidative damage resulting in cell death.⁹ Given the
90 mechanism of action, artesunate may provide beneficial and therapeutic effects for intraepithelial
91 HPV disease.

92 Several studies demonstrate the pro-apoptotic effects of Artesunate by activating the
93 mitochondria-dependent pathway, including caspase-3/9 activation and cytochrome c release
94 from the mitochondria.¹³ It induces autophagy in uterine corpus endometrial carcinoma cells and
95 elevates reactive oxygen species in human bladder cancer cells and hepatocellular carcinoma
96 cells.¹⁴⁻¹⁶ Artesunate has demonstrated anti-angiogenic properties by downregulation VEGF and
97 angiopoietin-1 in myeloma cells.¹⁷⁻¹⁹ Its reported anti-cancer effects involve the formation of
98 alkaline radicals through an endoperoxide bridge, reacting with intracellular ferrous iron and
99 leading to cell death.²⁰ The overexpression of the transferrin receptor in cervical squamous cell
100 cancers and their precursors,²¹ cervical intraepithelial neoplasia (CIN), prompted a study of
101 cytotoxic effects of dihydroartemisinin (DHA), the bioactive form of Artesunate, on
102 papillomavirus-expressing epithelial cells.²² *In vitro* studies revealed that DHA had minimal
103 impact on normal cervical epithelial cells but had significantly induced cytotoxicity in HPV-
104 immortalized cervical cells.²² Administered as a local treatment in a canine nonclinical model
105 with a 100% known tumor growth rate with HPV-infection, DHA (2.22 mg dissolved in 100 μ l
106 dimethyl sulfoxide) reported to inhibit papillomavirus-induced tumor formation. In addition,
107 tumor-negative dogs developed antibodies against the HPV L1 capsid protein.²²

108

109 **Safety for Intravaginal Use**

110 In a multi-center dose-escalation phase 1 study in the United States, intravaginal
111 artesunate inserts (pessaries) were tested for safety, tolerability, and efficacy in women with
112 CIN2/3.¹ This “first-in-human” study demonstrated that intravaginal Artesunate for CIN2/3
113 treatment was safe, well tolerated, and resulted in self-limited adverse events that were graded I
114 and II. Reported AEs among participants who used 3 five-day artesunate cycles included chills

115 and flu-like symptoms (n=3, grade 1), vaginal (yeast) infection (n=1, grade II), dizziness or
116 headache (n=2, grade 1), non-infective cystitis (n=1, grade 2), vaginal pain or uterine cramping
117 (n=9, grade I), vaginal discharge (n=4, grade 1), vaginal pruritis (n=9, grade 1). In summary, 37
118 drug-related AEs were observed in this Phase I trial, of which 34 (92%) were grade I, and 3 (8%)
119 were grade 2. Reported grade 2 adverse events included vaginal yeast infection (n = 6), bacterial
120 vaginosis (n = 2), vaginal inflammation (n = 2), urinary tract infection (n = 2), and noninfective
121 cystitis (n = 1). Adverse events that were determined to be unrelated to the study medication
122 included: anxiety, insomnia, suicidal ideation, vaginal twitching, fever, flu-like symptoms in a
123 patient who developed a cold, body itching, chills, and eczema flare. No subjects withdrew from
124 the study because of intolerable side effects, and all 28 subjects included in the modified-
125 intention-to-treat analyses were able to complete their designated dosing regimen. No grade 3 or
126 4 adverse events were reported, and three subjects reported no noticeable side effects. Currently,
127 a randomized placebo-controlled phase II study of artesunate vaginal inserts in treatment of
128 CIN2/3 is enrolling subjects at several US sites, with no serious adverse events reported so far
129 (NCT04098744). Additionally, a phase II randomized trial of artesunate suppositories for
130 treating anal high-grade squamous intraepithelial lesions among HIV-negative individuals is
131 ongoing in the United States (NCT5555862)

132

133 **Summary of Artesunate Pharmacokinetics**

134 The pharmacokinetics (PK) measures of artesunate (AS) and dihydroartemisinin (DHA)
135 following intravenous (IV), intramuscular (IM), oral and rectal administration have been well
136 described.²³ These PK parameters include maximum concentration of the drug in the blood
137 (C_{max}), time to maximum concentration C_{max} (T_{max}), apparent clearance (CL/F) - the drug

138 concentration in the body in proportion to the rate of elimination, volume of distribution (V/F),
139 the area under the plasma concentration versus time curve (AUC) which expresses the total
140 amount of the drug in systemic circulation after administration, and half-life ($t_{1/2}$). IV
141 administration of AS quickly produces high maximum concentrations (C_{max}) of AS, higher than
142 any other method of administration. One example of this can be seen in a study of adults with
143 uncomplicated malaria which compared AS and DHA levels following IV and IM
144 administration, C_{max} values for AS when administered intravenously reached over 16,000ng/mL
145 while only reaching around 884mg/mL when administered intramuscularly.²⁴ Similarly, the
146 maximum concentration (C_{max}) of AS and DHA peak quickly following IV administration,
147 followed by a rapid decline. The average half-life of AS following IV administration of less than
148 fifteen minutes in multiple studies, with an observed clearance range of 2-3 L/kg/hr and a
149 volume range of 0.1-0.3 L/kg.²³ The hydrolysis of AS into DHA following IV administration is
150 similarly quick, with maximum DHA levels reached soon after IV AS administration. The T_{max}
151 for DHA after IV administration was consistently less than 25 minutes according to the observed
152 studies with DHA clearance averaging between 0.5-1.5 L/kg/hr and volume averaging between
153 0.5-1.0 L/kg.²³ The AUC of AS following IV administration of 120 mg AS in adults ranged
154 between 876ng*hr/ml in healthy volunteers²⁵ and 1038 - 1269ng*hr/ml in those with malaria.²⁶
155 The AUC of DHA following IV administration of 120 mg AS in adults ranged from 1850
156 ng*hr/ml in healthy volunteers²⁷ to 1845-2377ng*hr/ml in those with malaria.²⁸

157 Compared to IV administration, IM administration produces lower peaks, longer half-life,
158 and higher volumes of distribution for AS, as well as delayed peaks for DHA. For example, AS
159 half-life following in IV administration is less than 15 minutes on average, compared to 25.2 to
160 48.2 minutes with IM administration.²³ Other parameters – in including DHA half-life, volume

161 of distribution, and clearance rates following IM administration resembled the values recorded
162 after IV administration in multiple studies, due to the high bioavailability, assessed by exposure
163 to DHA, associated with IM AS administration (>86%).²³ The AUC of AS following IM
164 administration of 120 mg AS in adults ranged between 856²⁹ - 999²⁵ ng*hr/ml in those with
165 malaria. The AUC of DHA following IM administration of 120 mg of AS in adults with malaria
166 was 2474 ng*hr/ml in one study.²⁵

167 When AS is administered orally, DHA peak concentrations (C_{max}), AUC, and half-life
168 averages are all notably higher than comparable AS parameters. The average time to DHA C_{max}
169 and half-life following oral AS administration (200 mg/day) are 2 hours, and 0.5-1.5 hours,
170 respectively, compared to one hour and 20-45 minutes, respectively, for AS.²³ While a similar
171 pattern is seen following IV and IM administration, namely, elevated levels of DHA half-life and
172 AUC compared to AS, the difference are notable following oral administration. Also, while oral
173 administration of AS results in a higher DHA C_{max} compared to AS, IV and IM administration
174 result in a notably higher AS C_{max} than DHA C_{max}. Morris et al (2011) points out that the
175 variations observed following oral administration are most likely attributed to AS functioning as
176 a “pro-drug” for DHA when ingested orally and in response to “first-pass or systemic
177 metabolism.”²³ Essentially, when AS is taken orally, it is converted to DHA at a greater extent
178 than when it is taken intravenously or intramuscularly. The AUC of AS and DHA in a study of
179 healthy adult volunteers taking 200mg AS daily for 5 days was 67 ng*hr/ml and 1158 ng*hr/ml
180 for AS & DHA, respectively, on Day 1, and 60 ng*hr/ml and 1300 ng*hr/ml for AS & DHA,
181 respectively, on Day 5.³⁰ Similar C_{max} parameters for AS were 67 ng/ml and 58 ng/ml on Day 1
182 and 5, respectively, and a pooled DHA C_{max} of 654 ng/ml, demonstrating the absence of time-
183 dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration of

184 200 mg artesunate.³⁰ The AUC of AS following oral administration of 200 mg AS in adults
185 ranged between 60-67ng*hr/ml in healthy volunteers³¹ and 310ng*hr/ml in those with malaria.³²
186 The AUC of DHA following oral administration of 200 mg of AS in adults ranged from 1158-
187 1331 ng*hr/ml^{31,33} in healthy volunteers to 3027ng*hr/ml in those with malaria.³² Rectal AS
188 administration yields pharmacokinetic results similar to those obtained from oral administration,
189 with the exception of delayed AS Cmax and longer AS half-life. Compared to IV administration,
190 expectedly, both AS absorption and elimination are prolonged following rectal administration.
191 Following rectal administration of AS, Tmax average between 0.58-1.43 hours, with a half-life
192 between 0.9-.95 hours.²³ These averages are based on three different studies: two studies
193 containing pediatric patients with uncomplicated falciparum malaria (10 - 20mg/Kg dosing)^{34,35}
194 and one study containing healthy Malaysian adults (200 mg rectal suppository, ~4mg/Kg
195 dosing).³⁶ Following rectal dosing of a one-time 200 mg AS suppository in healthy adults
196 (similar to our planned dosing), a Cmax, Tmax, half-life and AUC of 448.5 ng/ml, 1.43 hours,
197 0.95 hours, and 796 ng*hr/ml of AS were observed, and Cmax, Tmax, half-life and AUC of
198 385.6 ng/ml, 1.80 hours, 1.21 hours, and 965 ng*hr/ml respectively of DHA were observed in
199 healthy adults.³⁶ No data are available on rectal PK in adults with malaria as this route of
200 administration is not used to treat malaria in adults. The longer half-life of AS following rectal
201 dosing (average 0.9-0.95 hrs) compared to IM (average 25.2 – 48.2 minutes), or IV (average less
202 than 5 minutes) may reflect absorption rate-limited elimination of AS.²³ As is expected given
203 that rectal AS administration avoids by-pass metabolism, the discrepancy in AS and DHA AUC
204 values (796 ng*hr/ml and 965 ng*hr/ml, respectively), is not as striking with rectal, as compared
205 with oral administration of AS (119 ng*hr/ml and 1331 ng*hr/ml, respectively).²³ Similar to oral
206 administration, both DHA Tmax and half-life values were higher than that of AS following rectal

207 administration.²³

208

209 **Effect of malaria infection status on artesunate and DHA pharmacokinetics**

210 Teja-Isavadharm et al., conducted a direct comparison of DHA pharmacokinetics
211 following oral AS administration in healthy adults and falciparum malaria patients.³⁷ The
212 investigators found significantly higher AUC and Cmax of DHA in subjects with malaria as
213 compared to healthy subjects. Similar results were obtained by Binh et al in a study comparing
214 the PK in eight patients with falciparum malaria and ten healthy subjects³⁸ Due to the small size
215 of both studies, definitive conclusion regarding differences in PK between healthy and infected
216 subjects cannot be drawn.²⁷ However, as DHA clearance is dependent on hepatic blood flow, a
217 reduction in clearance, and consequently an increase in exposure associated with acute malaria
218 infection, would be consistent with known DHA's PK properties.²⁷

219

220 **Malaria treatment and artemisinin resistance**

221 Artemisinin-based combination therapies (ACTs) are recommended by the WHO as the
222 first line treatment for uncomplicated Plasmodium Falciparum.³⁹ In ACTs, artemisinin quickly,
223 and drastically, reduces the majority of malaria parasites, with the partner drug clearing the
224 remaining parasites to prevent recrudescence.^{40,41} Artemisinin resistance is defined as delayed
225 parasite clearance (following treatment with an artesunate monotherapy or ACT) observed as a
226 parasite clearance half-life greater than five hours or microscopic evidence of parasites on day
227 three.⁴² This represents partial resistance. While artemisinin resistance alone does not necessarily
228 lead to malaria treatment failure, reduced efficacy of the artemisinin component places greater
229 demands on the partner drug to clear a larger parasite mass, jeopardizing future efficacy (WHO).

230 Examples of ACTs include artemether-lumefantrine, artesunate-amodiaquine, artesunate-
231 mefloquine, among others. Standard ACTs regimen for uncomplicated malaria is an oral 3-day
232 course. Most studies indicate that current ACTs recommended in national malaria treatment
233 policies remain effective, with an overall efficacy rate of greater than 95%.⁴³

234 Artemisinin's act exceptionally fast against intra-erythrocytic asexual blood-stage malaria
235 parasites, affecting up to 10,000- fold reductions in parasite burden every 48 hours.⁴⁴ The
236 primary genetic drivers of artemisinin resistance, both *in vitro* and *in vivo*, are point mutations in
237 the *P. falciparum* Kelch13 (*PfK13*) gene during the early ring stage.^{45,46} These mutations allow a
238 subset of early ring-stage parasites to survive cell-cycle arrest brought on by artemisinin
239 exposure, enabling those parasites to reinitiate transcription and complete their intraerythrocytic
240 developmental cycle once artemisinin is no longer present at inhibitory concentrations.⁴⁷ *In vitro*
241 resistance is routinely defined as greater than 1% survival of early ring-stage parasites exposed to
242 700nM dihydroartemisinin (DHA-the primary active metabolite of ART) for 6 hours, followed
243 by drug-free culture incubation for a further 66 hours.⁴² The resistance mechanism appears to
244 involve a complex interplay of K13 protein abundance, hemoglobin endocytosis, and the parasite
245 response to stress.^{42,48}

246 In Africa, several studies have identified a number of low-frequency Pfk13 mutations
247 associated with delayed parasite clearance in four countries: Ghana, Rwanda, Uganda
248 Tanzania.^{49,50} Mutations including M476I, P553L, R561H, P574L, C580Y and A675V, were
249 observed at low frequencies under 5%.⁴⁹ For example, in Tanzania, mutations were found in two
250 parasites from 764 samples in 2027 (0.3%)⁶, and one parasite from 422 samples in 2019
251 (0.2%).⁴⁹ Similarly in Uganda, one parasite was identified from 796 samples in 2018/2019
252 (0.1%).⁵¹ A 2021 study in Northern Uganda from 2017 to 2019 identified *in vivo* artemisinin

253 resistance (parasite clearance half-life >5 hours) in a total of 14 out of 240 patients who received
254 intravenous artesunate.⁵¹ Of these 14 patients, 13 were infected with *P. falciparum* parasites with
255 mutations in the A675V or C469Y allele in the kelch13 gene.⁴⁶

256 *P. falciparum* resistance to artemisinin has been documented in five countries in
257 Southeast Asia; Cambodia, Lao People's Democratic Republic, Myanmar, Thailand and Vietnam
258 (WHO).⁴¹ With implementation of combination therapy, improvements to health systems and
259 surveillance systems to monitor first- and second-line treatment, the consequences of the
260 development of resistance to antimalarial medicines may be less severe today than what was
261 observed with chloroquine in the 1980s. If parasites develop reduced sensitivity to artemisinin,
262 ACTS will continue to cure malaria, as long as the partner drug remains effective.⁴¹ To
263 overcome resistance, potential changes can be made to ACT. Some of these include
264 modifications such as extending the duration of the ACT course (currently 3 days for oral
265 treatment), alternating use of different ACT regimens, and addition of another antimalarial drug
266 to the standard ACTs (triple-ACT).⁴¹ Additionally, adding a malaria vaccine (e.g. RTS, S
267 vaccine) to mass drug administration campaigns could enhance treatment efficacy and help
268 prevent further artemisinin resistance development.

269

270 **Systemic Artesunate absorption and possible implications for developing resistance for** 271 **malaria treatment.**

272 Although there is no available pharmacologic data on serum absorption following
273 intravaginal artesunate administration, this study aims to address this gap. The direct application
274 of artesunate to the cervical mucosa at the proposed dose of 200mg (≤ 4 mg/kg based on planned
275 inclusion criteria of weight ≥ 50 Kg) is unlikely to result in systemic absorption. This planned

276 dosage is 2.5-fold lower than the approved rectal suppository dose (10mg/Kg). In contrast to the
277 rectal mucosa, which is highly vascular and comprised of single-cell layer of columnar
278 epithelium making it highly permeable, the cervico-vaginal tissue has a thick, stratified
279 squamous epithelial cell layer and is significantly less vascular, reducing its systemic
280 absorption.⁵² Similarly, due to the rapid rate of elimination of Artesunate's active metabolite,⁵³
281 no systemic accumulation is expected of Artesunate or its active metabolite with intravaginal
282 multi-day dosing in the context of cervicovaginal administration.

283

284 **Methods**

285 **Study Objectives**

286 **Primary Objective**

287 The primary objective is to determine the area under the plasma concentration versus the
288 time curve (AUC) of DHA following five consecutive days of self-administration of Artesunate
289 vaginal inserts among healthy women living in Kenya

290

291 **Secondary Objectives**

- 292 1. Determine the area under the plasma concentration versus time curve (AUC) of
293 Artesunate (AS) following five consecutive days of self-administration of 200mg
294 Artesunate vaginal inserts (pessaries) among healthy women in Kenya
- 295 2. Determine the maximum concentration of Artesunate (AS) (C_{max}) following five
296 consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries)
297 among healthy women in Kenya

- 298 3. Determine the maximum concentration of dihydroartemisinin (DHA) (C_{max}) following
299 five consecutive days of self-administration of 200mg Artesunate vaginal inserts
300 (pessaries) among healthy women in Kenya
- 301 4. Determine the time to maximum concentration (T_{max}) of Artesunate (AS) following five
302 consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries)
303 among healthy women in Kenya
- 304 5. Determine the time to maximum concentration (T_{max}) of dihydroartemisinin (DHA)
305 following five consecutive days of self-administration of 200mg Artesunate vaginal
306 inserts (pessaries) among healthy women in Kenya
- 307 6. Determine the half-life (t_{1/2}) of Artesunate (AS) following five consecutive days of self-
308 administration of 200mg Artesunate vaginal inserts (pessaries) among healthy women in
309 Kenya
- 310 7. Determine the half-life (t_{1/2}) of dihydroartemisinin (DHA) following five consecutive
311 days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among
312 healthy women in Kenya
- 313 8. Determine the apparent clearance (CL/F) of Artesunate (AS) following five consecutive
314 days of self-administration of 200mg Artesunate vaginal inserts (pessaries) among
315 healthy women in Kenya
- 316 9. Determine the apparent clearance (CL/F) of dihydroartemisinin (DHA) following five
317 consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries)
318 among healthy women in Kenya

- 319 10. Determine the volume of distribution (V/F) of Artesunate (AS) following five
320 consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries)
321 among healthy women in Kenya
- 322 11. Determine the volume of distribution (V/F) of dihydroartemisinin (DHA) following five
323 consecutive days of self-administration of 200mg Artesunate vaginal inserts (pessaries)
324 among healthy women in Kenya
- 325 12. Investigate the safety of 5-day course of self-administered intravaginal artesunate vaginal
326 inserts (pessary) in women in Kenya

327

328 **Study design**

329 This is a single-arm, nonrandomized, interventional phase I study among 12 women over
330 the age of 18 living in Kisumu, Kenya. Participants will self-administer 200 mg artesunate
331 vaginal inserts for five consecutive days with blood draws performed on day 1 (at baseline) and
332 on day 5. Day 1 will consist of one blood draw prior to first pessary use and day 5 will consist of
333 eight blood draws: one prior to final artesunate administration, at time 0, then at 15 minutes, 30
334 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after final artesunate pessary insertion.

335

336 **Study setting**

337 This study will be conducted in Kisumu, Kenya at the Lumumba Sub-County Hospital
338 and at the Victoria Biomedical Research Institute. All study activities will take place at
339 Lumumba Sub-County Hospital except the day 5 study visit, which will take place at Victoria
340 Biomedical Research Institute.

341

342 **Eligibility and Recruitment**

343 **Recruitment**

344 Participants will be recruited from the general population within close proximity to the
345 study location in Kisumu County, which will include recruitment from local health facilities. The
346 study team will conduct local outreach activities and educational talks in the community to
347 harness interest in participating. If an individual is interested in participating, they will be
348 screened for eligibility and, if eligible, will provide their informed consent and will be briefed on
349 other study procedures before any study activities are performed.

350

351 **Inclusion & exclusion criteria**

352 Table 1: Inclusion and exclusion criteria for study participants

353

Inclusion Criteria	Exclusion Criteria
Age 18 years to 65 years	Current pregnancy or breastfeeding status
Negative pregnancy test at screening	History of total hysterectomy
Weight \geq 50 Kg at study entry*	Known allergy to Artesunate
Willingness to use contraception (hormonal or barrier) during the 5-day study dosing phase if of childbearing age (less than 50 years of age)	Have a medical comorbidity that in the opinion of the investigator would interfere with study participation
Ability and willingness to provide informed consent	Currently receiving artemisinin-based agents for malaria treatment or completed artemisinin-based treatment within the previous 3 days.**
Plan to reside in the study location during the study period	Male at birth

Agrees for samples without identifiers to be shipped outside of Kenya for testing

Current use of efavirenz antiretroviral therapy

Positive malaria antigen test at screening

354 *Justification for weight criteria: A minimum body weight of 50Kg will meet the planned
355 artesunate dosing of ≤ 4 mg/Kg for which excellent safety data is available.

356 **Based on dihydroartemisinin (artesunate's active metabolite) half-life of between 0.5-1.5
357 hours²⁹

358

359 **Study procedures by visit**

360 Pre-screening visit: Prior to enrollment of a participant, the study staff will pre-screen potential
361 participants at on-site or off-site locations. During these visits, study staff will explain the aspects
362 of the study to potential participants and will provide an explanation of eligibility requirements.

363

364 Screening/Enrollment visit: To begin the screening process, eligible participants will provide
365 their written informed consent for the study procedures. Once informed consent is obtained by
366 the study staff, the screening processes will begin, including a malaria antigen test to screen for
367 subacute malaria infection. If a participant tests positive for malaria, they will be referred for
368 treatment and considered screen failures, resulting in their discontinuation from participating in
369 the study. Given that the study is located in a malaria-endemic region, we have planned for a
370 high screening-to-enrollment ratio due to the likelihood of high rates of sub-clinical malaria.

371 Other screening and enrollment activities will involve the collection of basic demographic and
372 clinical data, study protocol training (including demonstration of intravaginal artesunate

373 application using a pelvic model), a limited physical and pelvic exam, a urine pregnancy test, and

374 a review of prohibited medications.

375

376 Visit 1: On the same day or up to 14 days after the screening and enrollment visit, the participant
377 will have their first study visit in the clinic. During this visit, eligibility will be confirmed, the
378 study protocol will be reviewed, and study staff will provide instructions on self-administering
379 artesunate. Additionally, the participant will have 2.5ml of blood drawn prior to their first
380 intravaginal self-administration of artesunate. Once self-administration of artesunate is complete,
381 the participant will insert a tampon and will be observed for 30 minutes prior to scheduling their
382 second visit on the following day.

383

384 Visits 2-4: Visits 2, 3, and 4 must occur within 24 hours of each other so the study staff will
385 attempt to schedule the visits at approximately the same time each day. During these visits, the
386 study staff will review and record any adverse events (AE) using a standardized questionnaire
387 and the U.S. National Cancer Institute Common Terminology Criteria for Adverse Events
388 (CTCAE). If an adverse event is scored a grade II or worse, a pelvic exam will be performed.
389 After review of adverse events, and reiteration of prohibited medications, the participant will be
390 asked to again self-administer artesunate followed by insertion of a tampon. Once they are
391 observed for 30 minutes, the following visit will be scheduled.

392

393 Visit 5: Visit 5 will occur no more than 24 hours after visit 4, with the study staff aiming to
394 schedule it at approximately the same time as the prior day's visit. During this visit, the study
395 staff will review and record adverse events, conducting a pelvic exam as needed based on the
396 grading of observed AEs. After AEs are reviewed and a reiteration of prohibited medications is

397 given, the participant will undergo their first 2.5ml blood draw of the visit before the insertion of
398 artesunate. A peripheral cannula will be inserted at this time for subsequent blood draws.

399 Following the initial blood draw, the participant will perform their final self-
400 administration of artesunate, followed by the insertion of a tampon. Once the final self-
401 administration of artesunate is complete, 2.5ml of blood will be drawn after 15 minutes, 30
402 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours. After the last blood draw, participants
403 will be scheduled for the final visit, which will take place 4-10 days after visit 5.

404

405 Visit 6: Visit 6 will occur 4-10 days after visit 5. During this visit, the study staff will review and
406 record adverse events since the last visit. Once AEs are recorded, the study staff will initiate
407 study termination and will provide the participant with any necessary financial reimbursement.

408

409 **Participant retention plan**

410 To ensure retention in the study, participants will be required to sign an informed consent
411 document indicating their clear understanding of the study procedures, duration, and any other
412 factors that are necessary to understand before consenting to participate. Once enrolled and
413 consented, the study staff will consistently follow-up with participants to ensure they attend all
414 scheduled appointments, to report any adverse event experiences, and to answer any questions
415 that the participant may have about their role in the study. To compensate for their time, each
416 participant will be reimbursed Kshs 1000 (approximately \$10) for each visit to account for
417 potential loss of wages and will be reimbursed for transport to and from the clinic. For the final
418 visit, which is expected to last up to 8 hours, participants will be reimbursed an additional Kshs
419 2,500 (\$25) for loss of wages. Participants may also receive refreshments during the visit

420 depending on how long they are asked to wait. If there is ever concern that a participant is lost to
421 follow-up, the study staff will make every effort to regain contact with the participant, whether
422 that be through calls or home visits.

423

424 **Statistical consideration**

425 **Sample size**

426 This study will have a sample size of 12 healthy volunteers.

427

428 **Sample size justification**

429 There are no prior data on the PK disposition of artesunate after intravaginal
430 administration and thus there is no data-related reason for the proposed sample size of 12 people.
431 This number was chosen as it is the standard number of patients evaluated in clinical PK studies
432 and it is adequate to perform pharmacokinetic plasma parameters of artesunate and DHA in order
433 to meet the study's primary objective.

434

435 **Data analysis**

436 The data analysis plan for this study involves assessing the primary outcome, which is the
437 plasma concentration versus time curve (AUC) of dihydroartemisinin following five days of self-
438 administration of 200mg Artesunate pessaries. With the primary endpoint being Mean DHA
439 AUC (ng*hr/ml) with standard deviation on Day 5, statistical analysis will compare this mean
440 DHA AUC to historical studies after intravenous (IV), oral, and rectal administration among
441 adults with similar dosing. Results will be analyzed using a student t-test for one-sample
442 observation and a p-value of 0.05 will be considered statistically significant.

443 The secondary outcomes include assessing the AUC of Artesunate, maximum
444 concentration of Artesunate and DHA (Cmax), time to reach maximum concentration (Tmax) for
445 Artesunate and DHA, half-life (t1/2) for Artesunate and DHA, apparent clearance of Artesunate
446 and DHA, and the volume of distribution of Artesunate and DHA. Statistical analysis of these
447 variables will include comparing data results to historical studies using relevant test materials.
448 The final outcome to be evaluated is the safety of the 5-day self-administration of Artesunate
449 vaginal inserts. This will be done by monitoring and reporting adverse events and categorizing
450 by their severity, with grade 3 or higher being considered severe. The proportion of participants
451 with a severe AE will be reported along the exact (Clopper-Pearson) one-sided upper 95%
452 confidence bounds. Safety among participants will be monitored and reported starting at the first
453 dose of artesunate.

454 This study will determine conventional pharmacokinetic parameters for Artesunate and
455 dihydroartemisinin (DHA). Parameters such as AUC, Cmax, Tmax, half-life, apparent clearance,
456 and the volume of distribution will be calculated using non compartmental analysis from the
457 plasma concentration-time data. AUC for Artesunate will be determined by linear trapezoidal
458 summation with extrapolation to infinity, starting from drug administration to the last
459 observation. All parameters will be calculated using time in hours after the first drug
460 administration. With respect to DHA, AUC will be calculated to the last drug measurable time
461 point. The elimination rate constant (beta) will be calculated from the slope of the terminal phase
462 of the log concentration-time profile, and the elimination half-life (t1/2) calculated from the ratio
463 of $\ln 2/\beta$. Other PK parameters will be calculated using standard model-independent
464 formulae.³⁹ The estimates of PK parameters for DHA will assume complete conversion of AS to

465 DHA as reported previously.³⁵ Data will be plotted graphically and analyzed using statistical
466 software. Data will be presented as mean with standard deviation (SD).

467

468 **Discussion**

469 Cervical cancer is preventable through vaccination against HPV, or screening for cervical
470 precancerous changes which can be treated. Access to cervical precancer treatment in low- and
471 middle-income countries is hindered by a shortage of trained healthcare provider and inadequate
472 health infrastructure. This results in a disproportionately high incidence and mortality rate from
473 this otherwise preventable disease. Use of self-administered topical therapies for cervical
474 precancer treatment, if found to be feasible and effective, can be transformative in increasing
475 access to secondary prevention of cervical cancer for marginalized women globally. Given
476 recent data demonstrating feasibility of topical Artesunate for treatment of HPV-associated
477 anogenital lesions, including vulvar and cervical precancer, it is imperative to understand the
478 pharmacokinetics of intravaginal use to inform studies using this drug in LMICs where malaria is
479 endemic.

480

481 **Current Status:**

482 The study opened for accrual in June 2024.

483

484 **Trial registration:**

485 The trial is registered under U.S Clinical trial registry (clinicaltrials.gov, NCT06263582).

486

487 **List of abbreviations**

488 **LMICs:** Low- and middle-income countries:

489 **AS:** Artesunate
490 **WHO:** World Health Organization
491 **CIN2/3:** High-grade cervical intraepithelial neoplasia
492 **HPV:** Human papillomavirus
493 **DHA:** Dihydroartemisinin
494 **PK:** Pharmacokinetics
495 **IV:** Intravenous
496 **IM:** Intramuscular
497 **ACTs:** Artemisinin-based combination therapies

498

499 **Declarations:**

500 **Ethics approval and consent to participate**

501 This clinical trial has full ethics review board approval from the University of North Carolina
502 Chapel Hill and the African Medical Research Foundation. Written informed consent will be
503 obtained from all study participants.

504

505 **Consent for publication**

506 Not applicable.

507

508 **Availability of data and materials**

509 Not applicable.

510

511 **Competing interests**

512 “The authors declare they have no competing interests.”

513

514 **Funding**

515 This research was supported by the Department of Obstetrics and Gynecology at University of
516 North Carolina-Chapel Hill. The content is solely the responsibility of the authors and does not
517 necessarily represent the official views of the National Institutes of Health. The study funders
518 have no role in the research.

519

520 **Authors' contributions**

521 CM conceived and designed the study, providing subject matter expertise and overseeing all
522 aspects of protocol development. JO (Co-Principal Investigator) provided guidance on protocol
523 development and will lead protocol implementation in country. JO and CO (Co-Investigator)
524 contributed to study design, protocol implementation, and capacity building for providers. KS
525 contributed to manuscript writing. GG contributes to lab management activities including
526 collection, storage, and shipment of samples. BM and CC contribute to in-country study
527 coordination activities. All authors, in their respective roles, contributed to study and manuscript
528 preparation and have collectively approved the final manuscript.

529

530 **Acknowledgements**

531 Not applicable.

532

533 **References**

- 534 1. Trimble CL, Levinson K, Maldonado L, et al. A first-in-human proof-of-concept trial of
535 intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3). *Gynecol*
536 *Oncol*. 2020;157(1):188-194. doi:10.1016/j.ygyno.2019.12.035
- 537 2. World Health Organisation. *World Health Organization. Guidelines for Treatment of*
538 *Malaria. 3rd Edition.*; 2015.
- 539 3. Bar-Zeev N, White N. Evidence behind the WHO guidelines: Hospital Care for Children:
540 efficacy and safety of artemisinin derivatives in children with malaria. *J Trop Pediatr*.
541 2006;52(2):78-82. doi:10.1093/tropej/fml005
- 542 4. Johann-Liang R, Albrecht R. Safety evaluations of drugs containing artemisinin
543 derivatives for the treatment of malaria. *Clin Infect Dis*. 2003;36(12):1626-1628.
544 doi:10.1086/375089
- 545 5. Nyaaba N, Andoh NE, Amoh G, et al. Comparative efficacy and safety of the artemisinin
546 derivatives compared to quinine for treating severe malaria in children and adults: A

- 547 systematic update of literature and network meta-analysis. *PLoS One*.
548 2022;17(7):e0269391. doi:10.1371/journal.pone.0269391
- 549 6. Ellis T, Eze E, Raimi-Abraham BT. Malaria and Cancer: a critical review on the
550 established associations and new perspectives. *Infect Agent Cancer*. 2021;16(1):33.
551 doi:10.1186/s13027-021-00370-7
- 552 7. Ma Z, Woon CYN, Liu CG, et al. Repurposing Artemisinin and its Derivatives as
553 Anticancer Drugs: A Chance or Challenge? *Front Pharmacol*. 2021;12:828856.
554 doi:10.3389/fphar.2021.828856
- 555 8. Jeong DE, Song HJJ, Lim S, et al. Repurposing the anti-malarial drug artesunate as a
556 novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor
557 growth, metastasis, and angiogenesis. *Oncotarget*. 2015;6(32):33046-33064.
558 doi:10.18632/oncotarget.5422
- 559 9. Efferth T, Sauerbrey A, Olbrich A, et al. Molecular modes of action of artesunate in
560 tumor cell lines. *Mol Pharmacol*. 2003;64(2):382-394. doi:10.1124/mol.64.2.382
- 561 10. Siegel EM, Patel N, Lu B, et al. Circulating biomarkers of iron storage and clearance of
562 incident human papillomavirus infection. *Cancer Epidemiol Biomarkers Prev*.
563 2012;21(5):859-865. doi:10.1158/1055-9965.EPI-12-0073
- 564 11. Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted
565 delivery of therapeutic agents against cancer. *Biochim Biophys Acta*. 2012;1820(3):291-
566 317. doi:10.1016/j.bbagen.2011.07.016
- 567 12. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus
568 infection. *Nat Rev Dis Primers*. 2016;2:16086. doi:10.1038/nrdp.2016.86
- 569 13. Wong YK, Xu C, Kalesh KA, et al. Artemisinin as an anticancer drug: Recent advances
570 in target profiling and mechanisms of action. *Med Res Rev*. 2017;37(6):1492-1517.
571 doi:10.1002/med.21446
- 572 14. Zhou X, Chen Y, Wang F, et al. Artesunate induces autophagy dependent apoptosis
573 through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder
574 cancer cells. *Chem Biol Interact*. 2020;331:109273. doi:10.1016/j.cbi.2020.109273
- 575 15. Zhang J, Zhou L, Xiang JD, Jin CS, Li MQ, He YY. Artesunate-induced ATG5-related
576 autophagy enhances the cytotoxicity of NK92 cells on endometrial cancer cells via
577 interactions between CD155 and CD226/TIGIT. *Int Immunopharmacol*. 2021;97:107705.
578 doi:10.1016/j.intimp.2021.107705
- 579 16. Yao X, Zhao CR, Yin H, Wang K, Gao JJ. Synergistic antitumor activity of sorafenib and
580 artesunate in hepatocellular carcinoma cells. *Acta Pharmacol Sin*. 2020;41(12):1609-
581 1620. doi:10.1038/s41401-020-0395-5
- 582 17. Gao F, Sun Z, Kong F, Xiao J. Artemisinin-derived hybrids and their anticancer activity.
583 *Eur J Med Chem*. 2020;188:112044. doi:10.1016/j.ejmech.2020.112044
- 584 18. Guan X, Guan Y. Artemisinin induces selective and potent anticancer effects in drug
585 resistant breast cancer cells by inducing cellular apoptosis and autophagy and G2/M cell
586 cycle arrest. *J BUON*. 2020;25(3):1330-1336.
- 587 19. Zhang B. Artemisinin-derived dimers as potential anticancer agents: Current
588 developments, action mechanisms, and structure-activity relationships. *Arch Pharm*
589 *(Weinheim)*. 2020;353(2):e1900240. doi:10.1002/ardp.201900240
- 590 20. Li D, Zhang J, Zhao X. Mechanisms and Molecular Targets of Artemisinin in Cancer
591 Treatment. *Cancer Invest*. 2021;39(8):675-684. doi:10.1080/07357907.2021.1954190
- 592 21. Anfosso L, Efferth T, Albin A, Pfeffer U. Microarray expression profiles of

- 593 angiogenesis-related genes predict tumor cell response to artemisinins.
594 *Pharmacogenomics J.* 2006;6(4):269-278. doi:10.1038/sj.tpj.6500371
- 595 22. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to
596 papillomavirus-expressing epithelial cells in vitro and in vivo. *Cancer Res.*
597 2005;65(23):10854-10861. doi:10.1158/0008-5472.CAN-05-1216
- 598 23. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the
599 clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin
600 following intravenous, intramuscular, oral or rectal administration. *Malar J.* 2011;10:263.
601 doi:10.1186/1475-2875-10-263
- 602 24. Ilett KF, Batty KT, Powell SM, et al. The pharmacokinetic properties of intramuscular
603 artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. *Br J Clin*
604 *Pharmacol.* 2002;53(1):23-30. doi:10.1046/j.0306-5251.2001.01519.x
- 605 25. Ilett KF, Batty KT, Powell SM, et al. The pharmacokinetic properties of intramuscular
606 artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria. *Br J Clin*
607 *Pharmacol.* 2002;53(1):23-30. doi:10.1046/j.0306-5251.2001.01519.x
- 608 26. KF I, KT B, SM P, et al. The pharmacokinetic properties of intramuscular artesunate and
609 rectal dihydroartemisinin in uncomplicated falciparum malaria. *Br J Clin Pharmacol.*
610 2002;53(1):23-30. doi:10.1046/J.0306-5251.2001.01519.X
- 611 27. Morris CA, Duparc S, Borghini-Fuhrer I, Jung D, Shin CS, Fleckenstein L. Review of the
612 clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin
613 following intravenous, intramuscular, oral or rectal administration. *Malar J.* 2011;10:263.
614 doi:10.1186/1475-2875-10-263
- 615 28. Batty KT, Thu LT, Davis TM, et al. A pharmacokinetic and pharmacodynamic study of
616 intravenous vs oral artesunate in uncomplicated falciparum malaria. *Br J Clin*
617 *Pharmacol.* 1998;45(2):123-129. doi:10.1046/j.1365-2125.1998.00655.x
- 618 29. Hien TT, Davis TME, Chuong L V., et al. Comparative pharmacokinetics of
619 intramuscular artesunate and artemether in patients with severe falciparum malaria.
620 *Antimicrob Agents Chemother.* 2004;48(11):4234-4239. doi:10.1128/AAC.48.11.4234-
621 4239.2004
- 622 30. Diem Thuy LT, Ngoc Hung L, Danh PT, Na-Bangchang K. Absence of time-dependent
623 artesunate pharmacokinetics in healthy subjects during 5-day oral administration. *Eur J*
624 *Clin Pharmacol.* 2008;64(10):993-998. doi:10.1007/s00228-008-0506-6
- 625 31. Diem Thuy LT, Ngoc Hung L, Danh PT, Na-Bangchang K. Absence of time-dependent
626 artesunate pharmacokinetics in healthy subjects during 5-day oral administration. *Eur J*
627 *Clin Pharmacol.* 2008;64(10):993-998. doi:10.1007/S00228-008-0506-6
- 628 32. Krudsood S, Loareesuwan S, Tangpukdee N, et al. New fixed-dose artesunate-
629 mefloquine formulation against multidrug-resistant Plasmodium falciparum in adults: a
630 comparative phase IIb safety and pharmacokinetic study with standard-dose nonfixed
631 artesunate plus mefloquine. *Antimicrob Agents Chemother.* 2010;54(9):3730-3737.
632 doi:10.1128/AAC.01187-09
- 633 33. Navaratnam V, Mansor SM, Mordi MN, Akbar A, Abdullah MN. Comparative
634 pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy
635 volunteers. *Eur J Clin Pharmacol.* 1998;54(5):411-414. doi:10.1007/S002280050484
- 636 34. Sirivichayakul C, Sabchareon A, Pengsaa K, et al. Comparative study of the effectiveness
637 and pharmacokinetics of two rectal artesunate/oral mefloquine combination regimens for
638 the treatment of uncomplicated childhood falciparum malaria. *Ann Trop Paediatr.*

- 639 2007;27(1):17-24. doi:10.1179/146532807X170466
- 640 35. Halpaap B, Ndjave M, Paris M, Benakis A, Kremsner PG. Plasma levels of artesunate
641 and dihydroartemisinin in children with Plasmodium falciparum malaria in Gabon after
642 administration of 50-milligram artesunate suppositories. *Am J Trop Med Hyg.*
643 1998;58(3):365-368. doi:10.4269/ajtmh.1998.58.365
- 644 36. Navaratnam V, Mansor SM, Mordi MN, Akbar A, Abdullah MN. Comparative
645 pharmacokinetic study of oral and rectal formulations of artesunic acid in healthy
646 volunteers. *Eur J Clin Pharmacol.* 1998;54(5):411-414. doi:10.1007/s002280050484
- 647 37. Teja-isavadharm P, Watt G, Eamsila C, et al. Comparative pharmacokinetics and effect
648 kinetics of orally administered artesunate in healthy volunteers and patients with
649 uncomplicated falciparum malaria. *Am J Trop Med Hyg.* 2001;65(6):717-721.
650 doi:10.4269/AJTMH.2001.65.717
- 651 38. Binh TQ, Ilett KF, Batty KT, et al. Oral bioavailability of dihydroartemisinin in
652 Vietnamese volunteers and in patients with falciparum malaria. *Br J Clin Pharmacol.*
653 2001;51(6):541-546. doi:10.1046/J.1365-2125.2001.01395.X
- 654 39. Guidelines for the Treatment of Malaria - PubMed. Accessed October 22, 2023.
655 <https://pubmed.ncbi.nlm.nih.gov/26020088/>
- 656 40. Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-
657 based combination therapies. *Curr Opin Microbiol.* 2022;69:102193.
658 doi:10.1016/j.mib.2022.102193
- 659 41. Hanboonkunupakarn B, Tarning J, Pukrittayakamee S, Chotivanich K. Artemisinin
660 resistance and malaria elimination: Where are we now? *Front Pharmacol.* 2022;13.
661 doi:10.3389/FPHAR.2022.876282
- 662 42. Balikagala B, Fukuda N, Ikeda M, et al. Evidence of Artemisinin-Resistant Malaria in
663 Africa. *N Engl J Med.* 2021;385(13):1163-1171. doi:10.1056/NEJMoa2101746
- 664 43. Mathenge PG, Low SK, Vuong NL, et al. Efficacy and resistance of different
665 artemisinin-based combination therapies: a systematic review and network meta-analysis.
666 *Parasitol Int.* 2020;74. doi:10.1016/J.PARINT.2019.04.016
- 667 44. Tilley L, Straimer J, Gnädig NF, Ralph SA, Fidock DA. Artemisinin Action and
668 Resistance in Plasmodium falciparum. *Trends Parasitol.* 2016;32(9):682-696.
669 doi:10.1016/J.PT.2016.05.010
- 670 45. Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: Emergence,
671 mechanisms, and outlook. *Int J Parasitol Drugs Drug Resist.* 2021;16:102-118.
672 doi:10.1016/J.IJPDDR.2021.05.007
- 673 46. Mok S, Stokes BH, Gnädig NF, et al. Artemisinin-resistant K13 mutations rewire
674 Plasmodium falciparum's intra-erythrocytic metabolic program to enhance survival. *Nat*
675 *Commun.* 2021;12(1). doi:10.1038/S41467-020-20805-W
- 676 47. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of
677 artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo
678 drug-response studies. *Lancet Infect Dis.* 2013;13(12):1043-1049. doi:10.1016/S1473-
679 3099(13)70252-4
- 680 48. Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-
681 based combination therapies. *Curr Opin Microbiol.* 2022;69.
682 doi:10.1016/J.MIB.2022.102193
- 683 49. Ndwigwa L, Kimenyi KM, Wamae K, et al. A review of the frequencies of Plasmodium
684 falciparum Kelch 13 artemisinin resistance mutations in Africa. *Int J Parasitol Drugs*

- 685 *Drug Resist.* 2021;16:155-161. doi:10.1016/J.IJPDDR.2021.06.001
- 686 50. Moser KA, Madebe RA, Aydemir O, et al. Describing the current status of Plasmodium
- 687 falciparum population structure and drug resistance within mainland Tanzania using
- 688 molecular inversion probes. *Mol Ecol.* 2021;30(1):100-113. doi:10.1111/MEC.15706
- 689 51. Asua V, Conrad MD, Aydemir O, et al. Changing Prevalence of Potential Mediators of
- 690 Aminoquinoline, Antifolate, and Artemisinin Resistance Across Uganda. *J Infect Dis.*
- 691 2021;223(6):985-994. doi:10.1093/INFDIS/JIAA687
- 692 52. Squier CA, Mantz MJ, Schlievert PM, Davis CC. Porcine vagina ex vivo as a model for
- 693 studying permeability and pathogenesis in mucosa. *J Pharm Sci.* 2008;97(1):9-21.
- 694 doi:10.1002/jps.21077
- 695 53. Meshnick SR. Artemisinin: mechanisms of action, resistance and toxicity. *Int J Parasitol.*
- 696 2002;32(13):1655-1660. doi:10.1016/s0020-7519(02)00194-7